Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
activated killer T cells and dendritic cells
- Development stage
- Unknown
- Lead developer
- Chiba Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intradermal, Subcutaneous, Intravenous, Intranodal
01
Overview
AKT-DC is an autologous adoptive cell therapy protocol involving the co-administration of activated killer T cells (AKT) and dendritic cells (DC). Developed primarily for the adjuvant treatment of non-small cell lung cancer (NSCLC) following surgical resection, the therapy utilizes cells harvested from the patient's own regional lymph nodes. The dendritic cells function as professional antigen-presenting cells to stimulate a systemic immune response, while the activated killer T cells exert direct cytotoxic effects on residual tumor cells and micrometastases. A Phase III randomized controlled trial demonstrated that the addition of AKT-DC to standard chemotherapy significantly improved 5-year overall survival and recurrence-free survival in NSCLC patients.
- Other names
- autologous activated killer T cells and dendritic cellsAKT/DC therapy
Beyond the preview
Go deeper on activated killer T cells and dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on activated killer T cells and dendritic cells.